Authors: F. Faltus; J. Horáček; D. Seifertová Authors‘ workplace: Psychiatrická klinika 1. LF UK a VFN, Praha, přednosta prof. MUDr. J. Raboch, DrSc. Psychiatrické centrum Praha, ředitel prof. MUDr. C. Höschl, DrSc. Published in: Čes. a slov. Psychiat., , 2000, No. 2, pp. 77-85. Category:
Quetiapine (Seroquel) is a new atypical dibenzothiazepine antipsychotic indicated for the treat-ment of schizophrenia. Like clozapine, quetiapine binds with a variety of neurotrainsmitter re-ceptor sites. Quetiapine has the greatest affinity for a1-adrenergic, H1-histaminergic and s(sigma) receptors. It has also an appreciable affinity for 5HT2-serotonergic a2 adrenergic andD2-dopaminergic receptors. The advance is virtually no affinity for benzodiazepine and muscari-nergic receptors. The beneficial receptor profile of quetiapine is responsible for the unique clini-cal characteristics. The efficacy in relation to schizophrenic symptoms is comparable withhaloperidol and chlorpromazine. Quetiapine produces only a minimum of side effects. The inci-dence of extrapyramidal symptoms is not different form placebo and quetiapine is not associatedwith increases in plasma prolactin levels. Quetiapine treatment is not associated with ECG abnor-malities, haematotoxicity and there are only few significant drug interactions.
Key words: quetiapine, Seroquel, schizophrenia, atypical antipsychotic.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
